A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol ...

DelveInsight’s “Plaque Psoriasis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the ...

Tremfya (guselkumab) has received approval from the US Food and Drug Administration (FDA) for paediatric patients with plaque ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...

(Reuters) -Bristol Myers Squibb said on Thursday it will sell its psoriasis drug Sotyktu directly to cash-paying patients at a more than 80% discount to the drug's list price. Bristol will start ...

All of the DTC channels offer discounts for people willing and able to pay for medicines with cash, and that also applies to ...

First results from the BeNeBio study show that doses of IL-17 and IL-23 inhibitors can be reduced by up to 50% in people with ...

GLP-1 RA treatment in psoriasis reduced risk for all-cause mortality, major adverse cardiac events, and alcohol and substance abuse.

The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 ...